Clinical trial
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
NCT03763604 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
- Lead sponsor
- Eli Lilly and Company
- Phase
- Expanded access
- Overall status
- Approved for marketing
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 160
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic breast cancer